Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
Announced that the U.S. FDA granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus (CLE) and will present new Phase 2 data on March 28, 2026. This designation is expected to have a low price impact of at least 1%, scheduled.
Korean Translation
미국 FDA가 피부 홍반성 루푸스(CLE) 치료제 리티필리맙(litifilimab)에 대해 혁신 치료제 지정을 부여했으며, 2026년 3월 28일에 새로운 2상 임상 데이터를 발표할 것이라고 밝힘. 이 지정은 최소 1%의 낮은 주가 영향을 미칠 것으로 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM